Xiangrong Peng
Overview
Explore the profile of Xiangrong Peng including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
24
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Peng X, Liu C, Zhang L, Chen Y, Mao L, Gao S, et al.
Front Pharmacol
. 2024 Jun;
15:1365683.
PMID: 38873416
IL4I1, also known as Interleukin-4-induced gene 1, is an enzyme that can modulate the immune system by acting as a L-amino acid oxidase. Nevertheless, a precise understanding of the correlation...
2.
Shi X, Peng X, Chen Y, Shi Z, Yue C, Zuo L, et al.
Front Immunol
. 2023 Dec;
14:1326509.
PMID: 38130721
Introduction: Methylenetetrahydrofolate dehydrogenase 2 (MTHFD2), whose aberrant expression is common in cancers, has recently been identified as a potential regulator of immune response. However, its immune-related role in bladder cancer...
3.
Gold Nanostars Combined with the Searched Antibody for Targeted Oral Squamous Cell Carcinoma Therapy
Cai L, Wang Y, Peng X, Li W, Yuan Y, Tao X, et al.
ACS Biomater Sci Eng
. 2022 May;
8(6):2664-2675.
PMID: 35603744
Oral squamous cell carcinoma (OSCC) is the most common cancer in the oral and maxillofacial region. Due to the special physiological and anatomical position of the oral cavity, the disease...
4.
Duan L, Wang C, Wang X, Wang A, Xu T, Peng X, et al.
NeuroRehabilitation
. 2021 Nov;
50(1):101-104.
PMID: 34776420
Background: Studies have shown that hyperbaric oxygen therapy (HBOT) can improve the extraction rate and latency of cortical evoked potential N20 in patients with severe traumatic brain injury, but there...
5.
Wang Y, Feng M, Lin B, Peng X, Wang Z, Lv R
Nanoscale
. 2021 Oct;
13(43):18125-18133.
PMID: 34605506
In this research, degradable peptide-modified upconversion nanoparticles (ZUPEA) were designed for the NIR II imaging and upconversion luminescence (UCL) guided photodynamic therapy (PDT) of triple-negative breast cancer (TNBC). Ultra-small rare-earth...
6.
Dai R, Peng X, Lin B, Xu D, Lv R
Bioconjug Chem
. 2021 Sep;
32(9):2117-2127.
PMID: 34470215
In this research, a NIR II luminescence imaging and enhanced chemo-/photothermal therapy system of CuS-DOX-Nd/FA NPs for breast cancer and lymph node tracing under single 808 nm irradiation is proposed....
7.
Lv R, Wang Y, Lin B, Peng X, Liu J, Lu W, et al.
Anal Chem
. 2021 Mar;
93(11):4984-4992.
PMID: 33705098
In this research, the antibody of the searched hub genes has been proposed to combine with a rare-earth composite for an upconversion luminescence (UCL) and downconversion (DCL) NIR-II imaging strategy...
8.
Liu J, Yang F, Feng M, Wang Y, Peng X, Lv R
ACS Biomater Sci Eng
. 2021 Jan;
5(10):5051-5059.
PMID: 33455252
In this research, we design the integration of Au/Ag nanocages with upconversion nanoparticles (UCNPs) as the theranostic agent under single 808 nm with enhanced imaging-guided photodynamic therapy (PDT) and photothermal...
9.
Feng M, Wang Y, Lin B, Peng X, Yuan Y, Tao X, et al.
Dalton Trans
. 2020 Jun;
49(27):9444-9453.
PMID: 32597918
In this research, a pH-sensitive degradable nanoprobe was designed by combining hydrophobic rare earth nanoparticles with biocompatible mPEG-PLGA nanomicelles for near infrared II (NIR-II) imaging-guided anti-tumor chemotherapy. The as-synthesized nanoprobes...